Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Viracept (Nelfinavir) Label Change Reflects Drug-Drug Interaction Information With Warfarin

From U.S. Food and Drug Administration

February 24, 2011

On February 24, 2011, FDA updated the Viracept (nelfinavir) label to include drug-drug interaction information between nelfinavir and wafarin.

Table 11 (Established and Other Potentially Significant Drug Interactions) of the Precautions section of the label was changed to add the following:

Coadministration of wafarin and Viracept may affect concentrations of wafarin. It is recommended that the INR (international normalized ratio) be monitored carefully during treatment with Viracept, especially when commencing therapy.

The complete, revised label will be posted soon at Drugs@FDA




  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
 
See Also
More on HIV Medications
More News on Nelfinavir (Viracept)
No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement